•     ICE was founded in 2010, an innovative CRO+ company focusing in early drug discovery services from target validation to PCC identification, with strong capabilities of in vitro biology technologies in the fields of I/O, cardiovascular and CNS diseases.
•     Aim to support innovative project exploration with partners
•     In house 100+ ion channels, 400+ Kinases, 100+ GPCRs, 30+ nuclear receptors assays are ready-to-use
•     State-of-the-art facilities to support multiple types of assays optimization and screening

•     With 6000+ m2  laboratory space, over 130 employees in Beijing and ~30 in Xuzhou